Sarcoplasmic reticulum Ca²⁺ ATPase as a therapeutic target for heart failure

Bibliography

• Rosamond W, Flegal K, Furie K, Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117(4):e25-146
   PubMed Web of Science ®Google Scholar
• Jessup M, Brozena S; Heart failure. N Engl J Med 2003;348(20):2007-18
   Google Scholar
• Lipskaia L, Ly H, Kawase Y, Treatment of heart failure by calcium cycling gene therapy. Future Cardiology 2007;3(4):413-23
   PubMedGoogle Scholar
• Del Monte F, Hajjar RJ. Intracellular devastation in heart failure. Heart Fail Rev 2008;13(2):151-62
   PubMed Web of Science ®Google Scholar
• Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med 2008;5(9):554-65
   PubMedGoogle Scholar
• Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008;70:23-49
   PubMed Web of Science ®Google Scholar
• Lipskaia L, Hulot JS, Lompre AM. Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pflugers Arch 2009;457(3):673-85
   PubMed Web of Science ®Google Scholar
• Sakata S, Lebeche D, Sakata N, Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 2007;42(4):852-61
   PubMed Web of Science ®Google Scholar
• Sakata S, Lebeche D, Sakata Y, Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther 2006;13(5):987-96
   PubMed Web of Science ®Google Scholar
• del Monte F, Lebeche D, Guerrero JL, Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 2004;101(15):5622-7
   PubMed Web of Science ®Google Scholar
• Hadri L, Lipskaia L, Kawase Y, SERCA2a overexpression induces eNOS activation in human coronary artery endothelial cells. Circ Res 2007;101:E65
   Web of Science ®Google Scholar
• Lipskaia L, del Monte F, Capiod T, Sarco/endoplasmic reticulum Ca2+ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 2005;97(5):488-95
   PubMed Web of Science ®Google Scholar
• Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res 2008;102(12):1458-70
   PubMed Web of Science ®Google Scholar
• Lyon AR, Sato M, Hajjar RJ, Gene therapy: targeting the myocardium. Heart 2008;94(1):89-99
   PubMed Web of Science ®Google Scholar
• Nicolaou P, Hajjar RJ, Kranias EG. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 2009;47(3):365-71
   PubMed Web of Science ®Google Scholar
• MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4(7):566-77
   PubMed Web of Science ®Google Scholar
• Bobe R, Bredoux R, Corvazier E, How many Ca2+ATPase isoforms are expressed in a cell type? A growing family of membrane proteins illustrated by studies in platelets. Platelets 2005;16(3-4):133-50
   PubMed Web of Science ®Google Scholar
• Periasamy M, Kalyanasundaram A. SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve 2007;35(4):430-42
   PubMed Web of Science ®Google Scholar
• Vangheluwe P, Tjwa M, Van Den Bergh A, A SERCA2 pump with an increased Ca2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J Mol Cell Cardiol 2006;41(2):308-17
   PubMed Web of Science ®Google Scholar
• Ver Heyen M, Heymans S, Antoons G, Replacement of the muscle-specific sarcoplasmic reticulum Ca2+-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction–relaxation of the heart. Circ Res 2001;89(9):838-46
   PubMed Web of Science ®Google Scholar
• O'Donnell JM, Fields A, Xu X, Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo. Am J Physiol Heart Circ Physiol 2008;295(6):H2483-94
   PubMed Web of Science ®Google Scholar
• del Monte F, Harding SE, Schmidt U, Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999;100(23):2308-11
   PubMed Web of Science ®Google Scholar
• Lipskaia L, Pinet C, Fromes Y, Mutation of δ-sarcoglycan is associated with Ca2+-dependent vascular remodeling in the Syrian hamster. Am J Pathol 2007;171(1):162-71
   PubMed Web of Science ®Google Scholar
• Vandebrouck A, Ducret T, Basset O, Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes. FASEB J 2006;20(1):136-8
   PubMedGoogle Scholar
• del Monte F, Williams E, Lebeche D, Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation 2001;104(12):1424-9
   PubMed Web of Science ®Google Scholar
• Venetucci LA, Trafford AW, O'Neill SC, Eisner DA. The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc Res 2008;77(2):285-92
   PubMed Web of Science ®Google Scholar
• Keller M, Kao JP, Egger M, Niggli E. Calcium waves driven by “sensitization” wave-fronts. Cardiovasc Res 2007;74(1):39-45
   PubMed Web of Science ®Google Scholar
• Davia K, Bernobich E, Ranu HK, SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol 2001;33(5):1005-15
   PubMed Web of Science ®Google Scholar
• Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7(8):589-600
   PubMed Web of Science ®Google Scholar
• Wilkins BJ, De Windt LJ, Bueno OF, Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 2002;22(21):7603-13
   PubMed Web of Science ®Google Scholar
• Liu Q, Wilkins BJ, Lee YJ, Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. Mol Cell Biol 2006;26(10):3785-97
   PubMed Web of Science ®Google Scholar
• Suzuki J, Bayna E, Li HL, Lipopolysaccharide activates calcineurin in ventricular myocytes. J Am Coll Cardiol 2007;49(4):491-9
   PubMed Web of Science ®Google Scholar
• Nakayama H, Otsu K, Yamaguchi O, Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 2003;17(1):61-3
   PubMedGoogle Scholar
• Sakata S, Lebeche D, Sakata Y, Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol 2007;292(2):H1204-7
   PubMed Web of Science ®Google Scholar
• Pleger ST, Harris DM, Shan C, Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 2008;102(7):786-94
   PubMed Web of Science ®Google Scholar
• He H, Giordano FJ, Hilal-Dandan R, Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 1997;100(2):380-9
   PubMed Web of Science ®Google Scholar
• Byrne MJ, Power JM, Preovolos A, Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008;15(23):1550-7
   PubMed Web of Science ®Google Scholar
• Chen Y, Escoubet B, Prunier F, Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 2004;109(15):1898-903
   PubMed Web of Science ®Google Scholar
• Prunier F, Kawase Y, Gianni D, Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation 2008;118(6):614-24
   PubMed Web of Science ®Google Scholar
• Kawase Y, Ly HQ, Prunier F, Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008;51(11):1112-9
   PubMed Web of Science ®Google Scholar
• Hajjar RJ, Zsebo K, Deckelbaum L, Design of a Phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008;14(5):355-67
   PubMed Web of Science ®Google Scholar
• Kaye DM, Preovolos A, Marshall T, Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007;50(3):253-60
   PubMed Web of Science ®Google Scholar
• Tsuji T, Del Monte F, Yoshikawa Y, Rescue of Ca2+ overload-induced left ventricular dysfunction by targeted ablation of phospholamban. Am J Physiol Heart Circ Physiol 2009;296(2):H310-7
   PubMed Web of Science ®Google Scholar
• Dieterle T, Meyer M, Gu Y, Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 2005;67(4):678-88
   PubMed Web of Science ®Google Scholar
• del Monte F, Harding SE, Dec GW, Targeting phospholamban by gene transfer in human heart failure. Circulation 2002;105(8):904-7
   PubMed Web of Science ®Google Scholar
• Ziolo MT, Martin JL, Bossuyt J, Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function. Circ Res 2005;96(8):815-7
   PubMed Web of Science ®Google Scholar
• Suckau L, Fechner H, Chemaly E, Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009;119(9):1241-52
   PubMed Web of Science ®Google Scholar
• Schmitt JP, Kamisago M, Asahi M, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003;299(5611):1410-3
   PubMed Web of Science ®Google Scholar
• Haghighi K, Kolokathis F, Gramolini AO, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA 2006;103(5):1388-93
   PubMed Web of Science ®Google Scholar
• Haghighi K, Kolokathis F, Pater L, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003;111(6):869-76
   PubMed Web of Science ®Google Scholar
• Pathak A, del Monte F, Zhao W, Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 2005;96(7):756-66
   PubMed Web of Science ®Google Scholar
• Nicolaou P, Rodriguez P, Ren X, Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 2009;104(8):1012-20
   PubMed Web of Science ®Google Scholar
• Most P, Remppis A, Pleger ST, S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007;293(2):R568-77
   PubMed Web of Science ®Google Scholar
• Most P, Pleger ST, Volkers M, Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004;114(11):1550-63
   PubMed Web of Science ®Google Scholar
• Pleger ST, Most P, Boucher M, Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007;115(19):2506-15
   PubMed Web of Science ®Google Scholar
• Rocchetti M, Alemanni M, Mostacciuolo G, Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model. J Pharmacol Exp Ther 2008;326(3):957-65
   PubMed Web of Science ®Google Scholar
• Micheletti R, Palazzo F, Barassi P, Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol 2007;99(2A):24A-32A
   PubMed Web of Science ®Google Scholar
• Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008;8(7):911-22
   PubMed Web of Science ®Google Scholar
• Samulski RJ. AAV vectors, the future workhorse of human gene therapy. Ernst Schering Res Found Workshop 2003;43:25-40
   PubMedGoogle Scholar
• Manno CS, Pierce GF, Arruda VR, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
   PubMed Web of Science ®Google Scholar
• Choi VW, Samulski RJ, McCarty DM. Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol 2005;79(11):6801-7
   PubMed Web of Science ®Google Scholar
• McCarty DM, Fu H, Monahan PE, Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10(26):2112-8
   PubMed Web of Science ®Google Scholar
• Li W, Asokan A, Wu Z, Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008;16(7):1252-60
   PubMed Web of Science ®Google Scholar
• Palomeque J, Chemaly ER, Colosi P, Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007;14(13):989-97
   PubMed Web of Science ®Google Scholar
• Pacak CA, Mah CS, Thattaliyath BD, Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006;99(4):e3-9
   PubMed Web of Science ®Google Scholar
• Raake PW, Hinkel R, Muller S, Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008;15(1):12-7
   PubMed Web of Science ®Google Scholar
• Inagaki K, Fuess S, Storm TA, Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14(1):45-53
   PubMed Web of Science ®Google Scholar
• Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008;16(7):1189-99
   PubMed Web of Science ®Google Scholar
• Wright MJ, Wightman LM, Lilley C, In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001;96(3):227-36
   PubMed Web of Science ®Google Scholar
• Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007;73(3):453-62
   PubMed Web of Science ®Google Scholar
• Hajjar RJ, Schmidt U, Matsui T, Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998;95(9):5251-6
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala S. An update on angiogenic gene therapy: vascular endothelial growth factor and other directions. Curr Opin Mol Ther 2006;8(4):295-300
   PubMed Web of Science ®Google Scholar
• Hayase M, Del Monte F, Kawase Y, Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 2005;288(6):H2995-3000
   PubMed Web of Science ®Google Scholar
• Preovolos A, Mennen M, Bilney A, Development of a novel perfusion technique to allow targeted delivery of gene therapy– the V-Focus system. J Extra Corpor Technol 2006;38:51-2
   PubMedGoogle Scholar
• Studeli R, Jung S, Mohacsi P, Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression. Am J Transplant 2006;6(4):775-82
   PubMed Web of Science ®Google Scholar
• Lowes BD, Gilbert EM, Abraham WT, Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346(18):1357-65
   PubMed Web of Science ®Google Scholar
• Terracciano CM, Hardy J, Birks EJ, Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 2004;109(19):2263-5
   PubMed Web of Science ®Google Scholar
• Vanderheyden M, Mullens W, Delrue L, Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 2008;51(2):129-36
   PubMed Web of Science ®Google Scholar
• Butter C, Rastogi S, Minden HH, Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol 2008;51(18):1784-9
   PubMed Web of Science ®Google Scholar
• Mullens W, Bartunek J, Wilson Tang WH, Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm 2008;5(1):52-9
   PubMed Web of Science ®Google Scholar
• Jaski BE, Jessup ML, Mancini DM, Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15(3):171-81
   PubMed Web of Science ®Google Scholar
• Yang L, Jiang J, Drouin LM, A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009;106(10):3946-51
   PubMed Web of Science ®Google Scholar
• Koerber JT, Jang JH, Schaffer DV. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008;16(10):1703-9
   PubMed Web of Science ®Google Scholar